TY - JOUR
T1 - Cardiac arrest in anti-mitochondrial antibody associated inflammatory myopathy
AU - Højgaard, Pil
AU - Witting, Nanna
AU - Rossing, Kasper
AU - Pecini, Redi
AU - Hartvig Lindkær Jensen, Thomas
AU - Hasbak, Philip
AU - Diederichsen, Louise P
N1 - © The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: [email protected].
PY - 2021/3
Y1 - 2021/3
N2 - Insight into predictors of cardiac involvement in inflammatory myopathies is sparse. A negative prognostic role of anti-mitochondrial antibodies (AMA) has been noticed and is supported by the current case. We describe a male patient who at the age 40 suffered a cardiac arrest and over the following months experienced progressive heart failure, arrhythmias and proximal muscle weakness. Clinical, genetic and serologic testing and repeated imaging- and histopathological investigations resulted in a diagnosis of AMA-associated, necrotizing, inflammatory myositis with cardiac involvement. Besides a cardiac resynchronization therapy defibrillator, heart failure and antiarrhythmic drugs the patient received successive immunosuppressants, which improved skeletal muscle strength but not cardiac disease progression. At age 45 he died from end-stage heart failure. Clinicians must be aware of AMA-associated myositis as a cause of unclarified heart disease, even in patients with initially sparse extra-cardiac manifestations. Further knowledge of treatment strategies is highly needed for this disease entity.
AB - Insight into predictors of cardiac involvement in inflammatory myopathies is sparse. A negative prognostic role of anti-mitochondrial antibodies (AMA) has been noticed and is supported by the current case. We describe a male patient who at the age 40 suffered a cardiac arrest and over the following months experienced progressive heart failure, arrhythmias and proximal muscle weakness. Clinical, genetic and serologic testing and repeated imaging- and histopathological investigations resulted in a diagnosis of AMA-associated, necrotizing, inflammatory myositis with cardiac involvement. Besides a cardiac resynchronization therapy defibrillator, heart failure and antiarrhythmic drugs the patient received successive immunosuppressants, which improved skeletal muscle strength but not cardiac disease progression. At age 45 he died from end-stage heart failure. Clinicians must be aware of AMA-associated myositis as a cause of unclarified heart disease, even in patients with initially sparse extra-cardiac manifestations. Further knowledge of treatment strategies is highly needed for this disease entity.
U2 - 10.1093/omcr/omaa150
DO - 10.1093/omcr/omaa150
M3 - Article
C2 - 33732479
SN - 2053-8855
VL - 2021
SP - 89
EP - 93
JO - Oxford Medical Case Reports
JF - Oxford Medical Case Reports
IS - 3
M1 - omaa150
ER -